These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36357573)

  • 1. A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia.
    Burke A; Borot F; Du X; Churchill M; Ding J; Grass AM; DeSouza P; Ali AM; Mukherjee S
    Oncogene; 2023 Jan; 42(1):26-34. PubMed ID: 36357573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
    Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
    Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia.
    Zeng X; Zhang H; Guo J; Yang D; Zhu Y; Liu N; Tang J; Liu T; Zhao X
    Cell Mol Life Sci; 2024 Aug; 81(1):371. PubMed ID: 39196413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
    Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
    PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells].
    Zhang T; Chen ML; Liu XY; He HZ; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):376-382. PubMed ID: 35680594
    [No Abstract]   [Full Text] [Related]  

  • 10. COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
    Klupsch K; Baeriswyl V; Scholz R; Dannenberg J; Santimaria R; Senn D; Kage E; Zumsteg A; Attinger-Toller I; von der Bey U; König-Friedrich S; Dupuy F; Lembke W; Albani C; Wendelspiess S; Dinkel L; Saro D; Hepler RW; Laszlo GS; Gudgeon CJ; Bertschinger J; Brack S; Walter RB
    Leukemia; 2019 Mar; 33(3):805-808. PubMed ID: 30206306
    [No Abstract]   [Full Text] [Related]  

  • 11. CD33 BiTE
    Marcinek A; Brauchle B; Rohrbacher L; Hänel G; Philipp N; Märkl F; Strzalkowski T; Lacher SM; Udiljak D; Spiekermann K; Theurich S; Kobold S; Kischel R; James JR; Bücklein VL; Subklewe M
    Cancer Immunol Immunother; 2023 Jul; 72(7):2499-2512. PubMed ID: 37041225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
    Zugmaier G; Klinger M; Schmidt M; Subklewe M
    Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
    Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
    Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC; Stein A
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
    Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
    PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
    Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
    Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.